| Title |
New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women’s Health
|
|---|---|
| Published in |
Drugs & Aging, January 2017
|
| DOI | 10.1007/s40266-017-0435-0 |
| Pubmed ID | |
| Authors |
Mark Jones, Susan Tett, Geeske M. E. E. Peeters, Gita D. Mishra, Annette Dobson |
| Abstract |
Extensive clinical research has consistently shown statins lower the risk of cardiovascular events and mortality. Some studies also suggest statins increase the risk of new-onset diabetes. Research to date has rarely included elderly women, hence little is known about the risk of diabetes after statin exposure in this population. Our objectives were to evaluate and estimate the risk of new-onset diabetes associated with statin exposure in a cohort of elderly Australian women. We performed an analysis of a population-based longitudinal cohort study with data linkage to the national death index and to national databases of non-hospital episodes of medical care and prescription medications dispensing. Participants included 8372 Australian women born between 1921 and 1926, alive at 1 January 2003, free of diabetes, and eligible for data linkage. Statin exposure was ascertained based on prescriptions dispensed between 1 July 2002 and 31 August 2013. Over 10 years of follow up, 49% of the cohort had filled a prescription for statins and 5% had initiated treatment for new-onset diabetes. Multivariable Cox regression showed statin exposure was associated with a higher risk of treatment for new-onset diabetes (hazard ratio 1.33; 95% confidence interval [CI] 1.04-1.70; p = 0.024). This equates to a number needed to harm (NNH) of 131 (95% CI 62-1079) for 5 years of exposure to statins. Risk increased with increasing dose of statin from the hazard ratio of 1.17 (95% CI 0.84-1.65) for the lowest dose to 1.51 (95% CI 1.14-1.99) for the highest dose. The dose-response for statins on new onset of diabetes suggests elderly women should not be exposed to higher doses of statins. Elderly women currently taking statins should be carefully and regularly monitored for increased blood glucose to ensure early detection and appropriate management of this potential adverse effect, including consideration of de-prescribing. |
X Demographics
The data shown below were collected from the profiles of 73 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 10 | 14% |
| United Kingdom | 7 | 10% |
| United States | 6 | 8% |
| Netherlands | 5 | 7% |
| Canada | 5 | 7% |
| Australia | 4 | 5% |
| Zimbabwe | 2 | 3% |
| Venezuela, Bolivarian Republic of | 2 | 3% |
| South Africa | 1 | 1% |
| Other | 4 | 5% |
| Unknown | 27 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 53 | 73% |
| Practitioners (doctors, other healthcare professionals) | 15 | 21% |
| Scientists | 5 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 75 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 16% |
| Student > Master | 11 | 14% |
| Student > Bachelor | 10 | 13% |
| Other | 6 | 8% |
| Student > Postgraduate | 6 | 8% |
| Other | 12 | 16% |
| Unknown | 19 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 11% |
| Nursing and Health Professions | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 9 | 12% |
| Unknown | 23 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 194. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2019.
All research outputs
#201,274
of 25,161,628 outputs
Outputs from Drugs & Aging
#3
of 1,297 outputs
Outputs of similar age
#4,524
of 431,281 outputs
Outputs of similar age from Drugs & Aging
#1
of 22 outputs
Altmetric has tracked 25,161,628 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,297 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,281 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.